Stio Life Science

the company stio – life science (sls) is a private joint stock company that was established in 2016 as the first egyptian company dedicated to providing “infection prevention & control-ipc” aiming “to achieve health for all”. shareholders structure stio is a family-owned company with an authorized capital of egp 50million and paid-in capital egp 15million. stio will focus on infection prevention and control (ipc). ipc is a practical proven set of organizational and technical approaches and measures to prevent the spread of avoidable infections and antimicrobial resistance (amr) within both community and health care settings. as of january 2020, stio has 7 products registered under its name in 32 different volumes and 2 products under registration. major product cost and expansion programs will be covered from retained earnings and depend mostly on self-financing. stio will build a large network of infection control specialists, physicians with different specialties, hospitals